Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2026-04-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于公司收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug re-registration approval notice from a regulatory authority (Chongqing Municipal Drug Administration). It details the drug's registration information, indications, and impact on the company. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no capital or financing updates, and no legal proceedings. The document is an official regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance-related disclosure.
2026-04-03 Chinese
关于参加独立董事培训并取得独立董事资格证书的承诺
Regulatory Filings Classification · 95% confidence The document is a short statement of commitment by an independent director candidate to obtain the required independent director qualification certificate as per regulatory requirements. It references compliance with listing rules and the Shenzhen Stock Exchange guidelines. There is no financial data, no report or announcement of financial results, no meeting materials, no voting results, no capital changes, or other typical financial or corporate filings. The document is a regulatory compliance statement related to corporate governance but does not fit into categories like Board/Management Information (MANG) since it is not announcing a change in board membership but a personal commitment. It is also not a certification or officer attestation in the typical sense but a formal regulatory filing. Given the lack of a more specific category, the best fit is Regulatory Filings (RNS). The document is very short and focused on regulatory compliance.
2026-04-01 Chinese
关于补选独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an independent director to the company's board. It details the nomination, qualifications, and compliance with regulatory requirements for the new independent director. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management discussion. The document is clearly about a change in the board composition, specifically the appointment of a new independent director. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1800 characters), consistent with an announcement rather than a full report.
2026-04-01 Chinese
独立董事提名人声明与承诺（梁咏梅）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It details qualifications, compliance with laws and regulations, and declarations about the nominee's independence and eligibility. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about director nomination and related compliance. The document length is 3374 characters, which is relatively short and consistent with a nomination statement rather than a full report. Therefore, the appropriate classification is Board/Management Information (MANG).
2026-04-01 Chinese
第四届董事会第四次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the fourth meeting of the fourth board of directors of Chongqing Huashen Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the approval of proposals such as the nomination of an independent director and the scheduling of an extraordinary general meeting. The content focuses on board decisions and changes related to board composition and governance matters. There is no financial data, earnings information, or report publication mentioned. The document fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and management-related decisions.
2026-04-01 Chinese
独立董事候选人声明与承诺（梁咏梅）
Regulatory Filings Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for Chongqing Huashen Pharmaceutical Co., Ltd. It includes statements of compliance with various regulatory requirements, qualifications, and independence criteria for serving as an independent director. There is no financial data, no report of financial results, no announcement of voting results, no management or board changes, and no mention of any meeting or report publication. The document is a regulatory compliance statement related to board candidate qualifications and independence, which does not fit into categories like Annual Report, Management Reports, or Proxy Solicitation. It is a formal regulatory filing related to governance and compliance but not a governance report itself. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other categories.
2026-04-01 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.